PDLIM5 and prostate carcinoma: Among men carrying the variant allele at the PDLIM5 SNPs rs1859962 or rs17021918 increased prostate cancer risk was observed with high compared to no terbufos use (OR = 2.05, 95% CI: 1.16–3.64, P-interaction = 0.037), (OR = 1.59, 95% CI: 1.03–2.45, P-interaction = 0.042), respectively (Table 3).